Cargando…

The Role of Bcl-2 Family Proteins in Therapy Responses of Malignant Astrocytic Gliomas: Bcl2L12 and Beyond

Glioblastoma (GBM) is a highly aggressive and lethal brain cancer with a median survival of less than two years after diagnosis. Hallmarks of GBM tumors include soaring proliferative indices, high levels of angiogenesis, diffuse invasion into normal brain parenchyma, resistance toward therapy-induce...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kouri, Fotini M., Jensen, Samuel A., Stegh, Alexander H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Scientific World Journal 2012
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3289992/ https://www.ncbi.nlm.nih.gov/pubmed/22431925 http://dx.doi.org/10.1100/2012/838916

Ejemplares similares

The prognostic influence of bcl-2 in malignant glioma
por: McDonald, F E, et al.
Publicado: (2002)

Bcl-B: an “unknown” protein of the Bcl-2 family
por: Pervushin, N. V., et al.
Publicado: (2023)

Bcl-2 family member Bcl-G is not a proapoptotic protein
por: Giam, M, et al.
Publicado: (2012)

Cancer-associated mutation and beyond: The emerging biology of isocitrate dehydrogenases in human disease
por: Tommasini-Ghelfi, Serena, et al.
Publicado: (2019)

BCL2DB: database of BCL-2 family members and BH3-only proteins
por: Rech de Laval, Valentine, et al.
Publicado: (2014)

Bcl-xL inhibition - a novel strategy for glioma therapy
por: Karpel-Massler, Georg, et al.
Publicado: (2016)

VDAC2 and the BCL-2 family of proteins
por: Yuan, Zheng, et al.
Publicado: (2021)

BCL-2 as therapeutic target for hematological malignancies
por: Perini, Guilherme Fleury, et al.
Publicado: (2018)

Bcl-2 Family Members Bcl-xL and Bax Cooperatively Contribute to Bortezomib Resistance in Mantle Cell Lymphoma
por: Luanpitpong, Sudjit, et al.
Publicado: (2022)

Bcl-xl as the most promising Bcl-2 family member in targeted treatment of chondrosarcoma
por: de Jong, Yvonne, et al.
Publicado: (2018)

Mcl‐1 and Bcl‐xL levels predict responsiveness to dual MEK/Bcl‐2 inhibition in B‐cell malignancies
por: Melvold, Katrine, et al.
Publicado: (2021)

BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival
por: Lee, Erinna F., et al.
Publicado: (2019)

Glioma Stem Cells Are Sensitized to BCL-2 Family Inhibition by Compromising Histone Deacetylases
por: Merati, Aran, et al.
Publicado: (2023)

Bcl-2 Expression in Pericytes and Astrocytes Impacts Vascular Development and Homeostasis
por: Zaitoun, Ismail S., et al.
Publicado: (2019)

Characterization of the signal that directs Bcl-x(L), but not Bcl-2, to the mitochondrial outer membrane
por: Kaufmann, Thomas, et al.
Publicado: (2003)

Molecular interactions of Bcl-2 and Bcl-xL with mortalin: identification and functional characterization
por: Saxena, Nishant, et al.
Publicado: (2013)

Bcl-2 and Bcl-x(L) Suppress Glucose Signaling in Pancreatic β-Cells
por: Luciani, Dan S., et al.
Publicado: (2013)

Roles and Regulation of BCL-xL in Hematological Malignancies
por: Morales-Martínez, Mario, et al.
Publicado: (2022)

Bioinformatic Analysis of the BCL-xL/BCL2L1 Interactome in Patients with Pancreatic Cancer
por: Magouliotis, Dimitrios E., et al.
Publicado: (2022)

Selective Affimers Recognise the BCL‐2 Family Proteins BCL‐x(L) and MCL‐1 through Noncanonical Structural Motifs
por: Miles, Jennifer A., et al.
Publicado: (2020)

Bcl-XL but Not Bcl-2 Is a Potential Target in Medulloblastoma Therapy
por: Westhoff, Mike-Andrew, et al.
Publicado: (2022)

The Bcl-2 Family in Host-Virus Interactions
por: Kvansakul, Marc, et al.
Publicado: (2017)

BCL-2 family isoforms in apoptosis and cancer
por: Warren, Chloe F. A., et al.
Publicado: (2019)

A comparative analysis of BCL-2 family
por: Choudhury, Shouhartha
Publicado: (2019)

Bcl10 mutations in malignancy
por: Dyer, M J S
Publicado: (1999)

Bax, Bcl-2, and Bax/Bcl-2 as prognostic markers in acute myeloid leukemia: are we ready for Bcl-2-directed therapy?
por: Kulsoom, Bibi, et al.
Publicado: (2018)

Inhibition of Bcl2L12 Attenuates Eosinophilia-Related Inflammation in the Heart
por: Chen, Xiao, et al.
Publicado: (2020)

Combined Targeting of JAK2 and Bcl-2/Bcl-xL to Cure Mutant JAK2-Driven Malignancies and Overcome Acquired Resistance to JAK2 Inhibitors
por: Waibel, Michaela, et al.
Publicado: (2013)

Disruption of Bcl-2 and Bcl-xL by viral proteins as a possible cause of cancer
por: Alibek, Kenneth, et al.
Publicado: (2014)

Effects of Bcl-2/Bcl-x(L) Inhibitors on Pulmonary Artery Smooth Muscle Cells
por: Rybka, Vladyslava, et al.
Publicado: (2018)

Hyperphosphorylation of BCL-2 family proteins underlies functional resistance to venetoclax in lymphoid malignancies
por: Chong, Stephen Jun Fei, et al.
Publicado: (2023)

Detection of Bcl-2 family member Bcl-G in mouse tissues using new monoclonal antibodies
por: Giam, M, et al.
Publicado: (2012)

BCL-G: 20 years of research on a non-typical protein from the BCL-2 family
por: Hartman, Mariusz L., et al.
Publicado: (2023)

BCL-2 protein family: attractive targets for cancer therapy
por: Kaloni, Deeksha, et al.
Publicado: (2022)

An antiapoptotic Bcl-2 family protein index predicts the response of leukaemic cells to the pan-Bcl-2 inhibitor S1
por: Zhang, Z, et al.
Publicado: (2013)

2-Deoxyglucose-induced toxicity is regulated by Bcl-2 family members and is enhanced by antagonizing Bcl-2 in lymphoma cell lines
por: Zagorodna, Oksana, et al.
Publicado: (2011)

Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity,
por: Lv, Dongwen, et al.
Publicado: (2021)

Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B
por: Rooswinkel, R W, et al.
Publicado: (2012)

Regulating Bcl2L12 expression in mast cells inhibits food allergy
por: Zheng, Peng-Yuan, et al.
Publicado: (2019)

Retraction: Inhibition of Bcl2L12 attenuates eosinophilia-related inflammation in heart
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_p9ij85kv6h01is2mg43jreuf89